Oncternal Therapeutics (ONCT) Scheduled to Post Earnings on Thursday

Oncternal Therapeutics (NASDAQ:ONCT – Get Rating) is set to release its earnings data after the market closes on Thursday, March 9th. Analysts expect Oncternal Therapeutics to post earnings of ($0.22) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Oncternal Therapeutics Trading Up 1.2 %

ONCT stock opened at $0.94 on Tuesday. The company has a market capitalization of $52.85 million, a PE ratio of -1.17 and a beta of 1.55. Oncternal Therapeutics has a 12-month low of $0.69 and a 12-month high of $1.87. The business’s fifty day moving average price is $1.07 and its 200 day moving average price is $1.03.

Institutional Investors Weigh In On Oncternal Therapeutics

Large investors have recently bought and sold shares of the stock. Millennium Management LLC increased its holdings in Oncternal Therapeutics by 98.3% during the 4th quarter. Millennium Management LLC now owns 1,159,745 shares of the company’s stock worth $1,160,000 after purchasing an additional 574,840 shares during the period. Renaissance Technologies LLC increased its holdings in Oncternal Therapeutics by 52.2% during the 3rd quarter. Renaissance Technologies LLC now owns 979,800 shares of the company’s stock worth $874,000 after purchasing an additional 336,066 shares during the period. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Oncternal Therapeutics during the 1st quarter worth about $585,000. Two Sigma Investments LP increased its holdings in shares of Oncternal Therapeutics by 136.0% in the 3rd quarter. Two Sigma Investments LP now owns 356,244 shares of the company’s stock valued at $318,000 after acquiring an additional 205,312 shares during the last quarter. Finally, Two Sigma Advisers LP increased its holdings in shares of Oncternal Therapeutics by 118.5% in the 3rd quarter. Two Sigma Advisers LP now owns 295,200 shares of the company’s stock valued at $263,000 after acquiring an additional 160,100 shares during the last quarter. Hedge funds and other institutional investors own 16.66% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald began coverage on Oncternal Therapeutics in a report on Thursday, December 22nd. They issued an “overweight” rating and a $4.00 price objective on the stock.

Oncternal Therapeutics Company Profile

(Get Rating)

Oncternal Therapeutics, Inc engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.